

June 28, 2024

Perseus Proteomics Inc.

[ir@ppmx.com](mailto:ir@ppmx.com)

### **PPMX-T003: Announcement of Publication of Paper Co-authored by Osaka University and Perseus Proteomics Related to ANKL Therapy**

Perseus Proteomics Inc. (“the Company”, President & CEO: Takuya Yokokawa, HQ: Tokyo) is pleased to announce that the paper co-authored by Professor Ai Kotani, Specially Appointed Associate Professor (Full Time) Ryo Yanagiya at Research Institute for Microbial Diseases, Osaka University, and the researchers of the Company, leading to elucidation of mechanism of action of PPMX-T003, an anti-transferrin receptor 1 antibody, has been published online in “Leukemia”, a US science journal.

ANKL is an ultra-rare disease with very poor prognosis and clarification of critical causes and establishment of standard therapy have been waited. The joint paper shows that LAT1, one of amino acid transporters, is expected to be an effective biomarker to predetermine the effectiveness of PPMX-T003 for ANKL.

Prof. Kotani’s research group and the Company have been jointly proceeding with research and development of therapeutic drugs against blood diseases including ANKL. Currently, an investigator-led phase I/II of ANKL is ongoing.

#### [Paper information]

Title: Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia

Journal: Leukemia

Author: Ryo Yanagiya, Yuji Miyatake, Natsumi Watanabe, Takanobu Shimizu, Akane Kanamori, Masaya Ueno, Sachiko Okabe, Joaquim Carreras, Shunya Nakayama, Ami Hasegawa, Kazuaki Kameda, Takeshi Kamakura, So Nakagawa, Takuji Yamauchi, Takahiro Maeda, Keisuke Ishii, Tadashi Matsuura, Hiroshi Handa, Atsushi Hirao, Kenichi Ishizawa, Makoto Onizuka, Tetsuo Mashima, Naoya Nakamura, Kiyoshi Ando, and Ai Kotani

URL: <https://www.nature.com/articles/s41375-024-02296-6>

Press release by Osaka University

<http://www.biken.osaka-u.ac.jp/en/achievement/research/2024/213>

END